Valneva publie ses résultats financiers du premier trimestre 2021 et fait un point sur ses activités
Valneva SE - American Depositary Shares (VALN)
Company Research
Source: GlobeNewswire
Très bonne avancée des programmes cliniques au premier trimestre 2021 pour : VLA15, actuellement le seul candidat vaccin en développement clinique contre la maladie de Lyme Initiation d’un nouvel essai de Phase 2 visant à accélérer le développement pédiatrique VLA2001, actuellement le seul candidat vaccin inactivé et adjuvanté en développement clinique contre la COVID-19 en Europe: Initiation d’une étude pivot de Phase 3Participation à la première étude mondiale sur la vaccination de rappel conduite au Royaume-UniPublication des résultats de Phase 1/2 VLA1553, seul programme vaccinal contre le chikungunya actuellement en Phase 3 dans le monde Recrutement terminé pour l’étude pivot de Phase 3 Succès de la cotation au Nasdaq au second trimestre; $107,6 millions de produit brut levé dans le cadre d’une offre publique aux Etats-Unis et d’un placement privé concomitant en EuropeTrésorerie et équivalents de trésorerie de €235,9 millions au 31 mars 2021 La trésorerie du premi
Show less
Read more
Impact Snapshot
Event Time:
VALN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VALN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VALN alerts
High impacting Valneva SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VALN
News
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate [Yahoo! Finance]Yahoo! Finance
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine CandidateGlobeNewswire
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F [Yahoo! Finance]Yahoo! Finance
- Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-FGlobeNewswire
- Valneva SE (NASDAQ: VALN) had its price target lowered by analysts at Guggenheim from $18.00 to $17.00. They now have a "buy" rating on the stock.MarketBeat
VALN
Sec Filings
- 3/26/24 - Form 6-K
- 3/22/24 - Form 20-F
- 3/22/24 - Form 6-K
- VALN's page on the SEC website